PARSACLISIB

Search structure
Synonyms:
Status: Phase 2
Entry Type: Small molecule
Molecule Category: UNKNOWN
UNII: OS7097575K

Structure
InChI Key ZQPDJCIXJHUERQ-QWRGUYRKSA-N
Smile CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1
InChI
InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C20H22ClFN6O2
Molecular Weight 432.89
AlogP 3.12
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 5.0
Polar Surface Area 107.95
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 30.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR PI3-kinase p110-delta subunit inhibitor PubMed PubMed Other
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
- 1-2 - - -
Ion channel Voltage-gated ion channel Potassium channels Voltage-gated potassium channel
- 75000 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Lymphoma, Follicular 3 D008224 ClinicalTrials
Lymphoma, Mantle-Cell 3 D020522 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Sjogren's Syndrome 2 D012859 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Pemphigus 2 D010392 ClinicalTrials
Anemia, Hemolytic, Autoimmune 2 D000744 ClinicalTrials
Myeloproliferative Disorders 2 D009196 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Breast Neoplasms 1 D001943 ClinicalTrials
Endometrial Neoplasms 1 D016889 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 1 D015451 ClinicalTrials
Melanoma 1 D008545 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 1 D016403 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 1426698-88-5
ChEMBL CHEMBL4297615
DrugBank DB14867
FDA SRS OS7097575K
Guide to Pharmacology 10098
PubChem 86677874
SureChEMBL SCHEMBL14736228
CONTENTS